GlassScriptPhysician profile
Shea Gerstenmaier
NPI 1790464501
$1,171.78
in general payments reported to CMS, 2019-2025
10 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $122 · 2023: $622 · 2024: $171 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $991 · Education: $58.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.41 |
| Education | $58.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $506.15 | 2022-2025 | Tezspire, Airsupra, Breztri |
| Genzyme Corporation | $257.40 | 2023-2024 | |
| Glaxosmithkline, LLC. | $90.94 | 2023-2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $90.54 | 2023 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $57.96 | 2023 | Dupixent |
| Intra-Sana Laboratories | $50.00 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Takeda Pharmaceuticals U.S.A., INC. | $47.42 | 2024-2025 | Glassia |
| Harmony Biosciences LLC | $27.53 | 2023 | Wakix |
| Mylan Specialty L.P. | $23.98 | 2023 | Yupelri |
| Insmed, INC. | $19.86 | 2025 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shea Gerstenmaier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.